As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.
12 Analysts have issued a Kiniksa Pharmaceuticals Ltd. Class A forecast:
12 Analysts have issued a Kiniksa Pharmaceuticals Ltd. Class A forecast:
| Jun '25 | 
    +/-
   
    %
   | ||
| Revenue | 529 529 | 
      
        
        56%
      
      
        
        56%
      
 | |
| Gross Profit | 455 455 | 
      
        
        53%
      
      
        
        53%
      
 | |
| EBITDA | 5.98 5.98 | 
      
        
        123%
      
      
        
        123%
      
 | |
| EBIT (Operating Income) EBIT | 4.48 4.48 | 
      
        
        116%
      
      
        
        116%
      
 | |
| Net Profit | 4.79 4.79 | 
      
        
        147%
      
      
        
        147%
      
 | |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.
| Head office | Bermuda | 
| CEO | Sanj Patel | 
| Employees | 315 | 
| Founded | 2015 | 
| Website | www.kiniksa.com | 
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


